LYSINE ASPARTATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H14N2O2.C4H7NO4
Molecular Weight	279.2902
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CC(O)=O)C(O)=O.NCCCC[C@H](N)C(O)=O

InChI

InChIKey=CPYVQXAASIFAMD-KNIFDHDWSA-N

InChI=1S/C6H14N2O2.C4H7NO4/c7-4-2-1-3-5(8)6(9)10;5-2(4(8)9)1-3(6)7/h5H,1-4,7-8H2,(H,9,10);2H,1,5H2,(H,6,7)(H,8,9)/t5-;2-/m00/s1

HIDE SMILES / InChI

Molecular Formula	C6H14N2O2
Molecular Weight	146.1876
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H7NO4
Molecular Weight	133.1027
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.nap.edu/read/10490/chapter/12
Curator's Comment: description was created based on several sources, including https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373

Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 4 (5-HT4) receptor 39 Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616	Antagonist 2778
GABA-A receptor; anion channel 202 Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8587651	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Herpes simplex infection 28 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine has been studied for the prevention and treatment of herpes infections and cold sores.
Angina pectoris 106 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine supplements may relieve effort-related angina pectoris.
Osteoporosis 97 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine increases the intestinal absorption and reduces the renal elimination of calcium.
Anxiety 267 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist
Heroin dependence 10 Sources: https://www.drugs.com/npp/lysine.html	Palliative	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine acetylsalicylate has been used to detoxify the body after heroin use.
Patent ductus arteriosus 8 Sources: https://www.drugs.com/pro/neoprofen.html	Primary	Approved 8429	NEOPROFEN Approved Use NeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Launch Date 2006

PubMed

Title	Date	PubMed
Antibodies to SOX13 (ICA12) are associated with type 1 diabetes.	2001	11264788
Assays for mitogen-activated protein kinase (MAPK) subtypes and MAPK activating protein kinase-2 (MAPKAP K-2) using a common cell lysate.	2001	11100471
Identification of the alpha-aminoadipic semialdehyde dehydrogenase-phosphopantetheinyl transferase gene, the human ortholog of the yeast LYS5 gene.	2001 Apr	11286508
Formation of 1,1'-iminodicarboxylic acid derivatives, 2,6-diketo-piperazine and dibenzodiazocine-2,6-dione by variations of multicomponent reactions.	2001 Apr	11233828
The number of morphological synapses between neurons does not predict the strength of their physiological synaptic interactions: a study of dendrites in the nematode Ascaris suum.	2001 Apr 16	11268011
Properties of microtubules assembled from mammalian tubulin synthesized in Escherichia coli.	2001 Apr 17	11294652
Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner.	2001 Apr 27	11278427
Ethanol production from wheat straw hemicellulose hydrolysate by Pichia stipitis.	2001 Apr 27	11267696
Biochemical and functional characterization of a molecule expressed by a subset of thymic medullary epithelial cells.	2001 Feb	11292258
Isolation of the Escherichia coli nucleoid.	2001 Feb	11278063
Detection of early gene expression changes during activation of human primary lymphocytes by in vitro synthesis of proteins from polysome-associated mRNAs.	2001 Feb	11266628
The effect of protease inhibitors on the two-dimensional electrophoresis pattern of red blood cell membranes.	2001 Feb	11258769
In vivo distribution and speciation of [114mIn]InCl3 in the Wistar rat.	2001 Feb	11253025
L-lysine reduces nonenzymatic glycation of glomerular basement membrane collagen and albuminuria in diabetic rats.	2001 Feb	11244310
Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease.	2001 Feb	11236841
How does endotoxin trigger inflammation in otitis media with effusion?	2001 Feb	11210878
Characterization of the lipopolysaccharide of Yersinia pestis.	2001 Feb	11162185
The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.	2001 Feb	11156641
Evidence that fragile X mental retardation protein is a negative regulator of translation.	2001 Feb 15	11157796
Uptake and accumulation of exogenous docosahexaenoic acid by Chlorella.	2001 Jan	11272831
Endotoxemia and acute-phase proteins in major abdominal surgery.	2001 Jan	11248174
Inhibition of the nitrosothiol production of cultured osteoarthritic chondrocytes by rhein, cortisol and diclofenac.	2001 Jan	11178941
Interaction of poly(rC)-binding protein 2 with the 5'-terminal stem loop of the hepatitis C-virus genome.	2001 Jan	11163645
Cryptosporidium infection in Bedouin infants assessed by prospective evaluation of anticryptosporidial antibodies and stool examination.	2001 Jan 15	11159166
Acceleration of thrombomodulin gene transcription by retinoic acid: retinoic acid receptors and Sp1 regulate the promoter activity through interactions with two different sequences in the 5'-flanking region of human gene.	2001 Jan 26	11036068
Isolation and characterization of a new ribosome inactivating protein, momorgrosvin, from seeds of the monk's fruit Momordica grosvenorii.	2001 Jan 5	11205869
Hsp90 regulates p50(cdc37) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase.	2001 Jan 5	11036079
The function of interdomain interactions in controlling nucleotide exchange rates in transducin.	2001 Jun 29	11290746
Chemical and biological evaluation of endotoxin contamination on natural rubber latex products.	2001 Jun 5	11255197
T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.	2001 Mar 1	11280767
Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles.	2001 Mar 1	11230513
Inositol phosphates from barley low-phytate grain mutants analysed by metal-dye detection HPLC and NMR.	2001 Mar 1	11171128
Effects of initial particle size on the tableting properties of L-lysine monohydrochloride dihydrate powder.	2001 Mar 14	11250107
Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.	2001 Mar 15	11289139
Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.	2001 Mar 15	11275975
High pressure increases bactericidal activity and spectrum of lactoferrin, lactoferricin and nisin.	2001 Mar 20	11294354
Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.	2001 Mar 21	11257391
Characterization of mouse brain-specific angiogenesis inhibitor 1 (BAI1) and phytanoyl-CoA alpha-hydroxylase-associated protein 1, a novel BAI1-binding protein.	2001 Mar 5	11245925
Influence of crystal shape on the tableting performance of L-lysine monohydrochloride dihydrate.	2001 May	11288101
Human corneal GlcNac 6-O-sulfotransferase and mouse intestinal GlcNac 6-O-sulfotransferase both produce keratan sulfate.	2001 May 11	11278593
Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site.	2001 May 11	11278580
Isolation and characterization of senescence-induced cDNAs encoding deoxyhypusine synthase and eucaryotic translation initiation factor 5A from tomato.	2001 May 18	11278418
CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity.	2001 May 25	11278503

Patents

Sample Use Guides

In Vivo Use Guide

Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.

Route of Administration: Oral

In Vitro Use Guide

In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:16:29 GMT 2023` Edited by `admin` on `Fri Dec 15 15:16:29 GMT 2023`
Record UNII	23227F83U0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LYSINE ASPARTATE

Official Name

English

L-LYSINE, L-ASPARTATE (1:1)

Common Name

English

L-LYSINE-L-ASPARTATE

Common Name

English

LYSINE L-ASPARTATE, L-

Common Name

English

LYSINE ASPARTATE [INCI]

Common Name

English

L-ASPARTIC ACID, COMPD. WITH L-LYSINE (1:1)

Common Name

English

LYSINE, L-, L-ASPARTATE (1:1)

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID80181785